中华实验和临床感染病杂志（电子版）
中華實驗和臨床感染病雜誌（電子版）
중화실험화림상감염병잡지（전자판）
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL INFECTIOUS DISEASES(ELECTRONIC VERSION)
2013年
5期
678-680
,共3页
叶峰%刘小静%张曦%李月礁%孔颖%杨雪亮%蔺淑梅%刘敏%刘昳
葉峰%劉小靜%張晞%李月礁%孔穎%楊雪亮%藺淑梅%劉敏%劉昳
협봉%류소정%장희%리월초%공영%양설량%린숙매%류민%류질
肝炎,丙型%干扰素类%肝硬化
肝炎,丙型%榦擾素類%肝硬化
간염,병형%간우소류%간경화
Hepatitis C%Interferons%Liver cirrhosis
目的：通过动态监测肝脏硬度值，了解抗病毒治疗对慢性HCV感染者肝纤维化程度的影响。方法选择60例慢性HCV感染者进行PegIFN联合RBV抗病毒治疗，以12周HCV RNA水平低于1000拷贝/ml为界限，分为HCV RNA低于检测下限组（A组）和HCV RNA未低于检测下限组（B组），动态监测这两组患者0（基线）、12、24周的肝脏硬度值；同时在基线时检测健康体检者的肝脏硬度值作为正常对照。结果治疗12周，A组有44例患者HCV RNA ＜1000拷贝/ml，B组有16例患者HCV RNA ≥1000拷贝/ml。基线时，两组肝脏硬度值比较差异无统计学意义（P =0.234），但均高于正常对照组（P =0.014）。A组组内比较，12周与基线无显著差异（P =0.061），24周与基线和12周有显著差异（P =0.013）；B组组内比较，基线、12周、24周之间的肝脏硬度值无显著差别（P=0.121、0.051、0.064）。组间比较，A组在12周时肝脏硬度值略低于B组，但无统计学差异（P =0.076），24周时A组的肝脏硬度值显著低于B组（P =0.046）。结论 PegIFN联合RBV在抗病毒的同时能够减轻慢性HCV感染者肝纤维化的程度，若患者出现HCV RNA低于检测下限，则肝纤维逆转效果更加明显。
目的：通過動態鑑測肝髒硬度值，瞭解抗病毒治療對慢性HCV感染者肝纖維化程度的影響。方法選擇60例慢性HCV感染者進行PegIFN聯閤RBV抗病毒治療，以12週HCV RNA水平低于1000拷貝/ml為界限，分為HCV RNA低于檢測下限組（A組）和HCV RNA未低于檢測下限組（B組），動態鑑測這兩組患者0（基線）、12、24週的肝髒硬度值；同時在基線時檢測健康體檢者的肝髒硬度值作為正常對照。結果治療12週，A組有44例患者HCV RNA ＜1000拷貝/ml，B組有16例患者HCV RNA ≥1000拷貝/ml。基線時，兩組肝髒硬度值比較差異無統計學意義（P =0.234），但均高于正常對照組（P =0.014）。A組組內比較，12週與基線無顯著差異（P =0.061），24週與基線和12週有顯著差異（P =0.013）；B組組內比較，基線、12週、24週之間的肝髒硬度值無顯著差彆（P=0.121、0.051、0.064）。組間比較，A組在12週時肝髒硬度值略低于B組，但無統計學差異（P =0.076），24週時A組的肝髒硬度值顯著低于B組（P =0.046）。結論 PegIFN聯閤RBV在抗病毒的同時能夠減輕慢性HCV感染者肝纖維化的程度，若患者齣現HCV RNA低于檢測下限，則肝纖維逆轉效果更加明顯。
목적：통과동태감측간장경도치，료해항병독치료대만성HCV감염자간섬유화정도적영향。방법선택60례만성HCV감염자진행PegIFN연합RBV항병독치료，이12주HCV RNA수평저우1000고패/ml위계한，분위HCV RNA저우검측하한조（A조）화HCV RNA미저우검측하한조（B조），동태감측저량조환자0（기선）、12、24주적간장경도치；동시재기선시검측건강체검자적간장경도치작위정상대조。결과치료12주，A조유44례환자HCV RNA ＜1000고패/ml，B조유16례환자HCV RNA ≥1000고패/ml。기선시，량조간장경도치비교차이무통계학의의（P =0.234），단균고우정상대조조（P =0.014）。A조조내비교，12주여기선무현저차이（P =0.061），24주여기선화12주유현저차이（P =0.013）；B조조내비교，기선、12주、24주지간적간장경도치무현저차별（P=0.121、0.051、0.064）。조간비교，A조재12주시간장경도치략저우B조，단무통계학차이（P =0.076），24주시A조적간장경도치현저저우B조（P =0.046）。결론 PegIFN연합RBV재항병독적동시능구감경만성HCV감염자간섬유화적정도，약환자출현HCV RNA저우검측하한，칙간섬유역전효과경가명현。
Objective Liver stiffness values are monitored dynamically to understand the effect of antiviral therapy on liver fibrosis of patients with chronic HCV infection. Methods Total of 60 patients with chronic HCV infection were selected for anti-viral therapy with pegylated interferon combined with ribavirin. HCV RNA level lower than 1000 copies/ml at 12th week was taken as the boundary, and these cases were divided into group A with the virus turning negative, and group B with the virus not turning negative. Liver stiffness values of the patients of these at 0 week (baseline), 12th week and 24th week. At the same time liver stiffness values of normal people were detected at 0 week to be the normal control. Results After 12 weeks of treatment, 44 patients’ HCV RNA < 1000 copies/ml (group A), and 16 patients’ HCV RNA ≥ 1000 copies/ml (group B). At 0 week, there was no difference in liver stiffness values between group A and group B (P = 0.234), but the two groups’ values were higher than that of the normal control group (P = 0.014). After the comparison within group A, there was no significant difference in liver stiffness values at 12th week with that at 0 week (P = 0.061), and there was significant difference in liver stiffness values at 24th week with that at the baseline and 12th week (P = 0.013). After the comparison within group B, there was no significant difference in liver stiffness values at 0 week, 12th week, and 24th week (P = 0.121, 0.051, 0.064). Through comparing two groups, liver stiffness values in group A were slightly lower than that in group B at 12th week, but there was no statistical difference (P = 0.076), and liver stiffness values in group A were significantly lower than that in group B at 24th week (P = 0.046). Conclusions Pegylated interferon combined with ribavirin can have antivirus function and also can alleviate the degree of hepatic fibrosis of patients with chronic HCV infection. If the virus turns negative, the reversal effect of hepatic fibrosis is more pronounced.
